atropine has been researched along with docetaxel anhydrous in 3 studies
| Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) | Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) |
|---|---|---|---|---|---|
| 26,711 | 1,259 | 1,697 | 12,110 | 3,216 | 6,920 |
| Protein | Taxonomy | atropine (IC50) | docetaxel anhydrous (IC50) |
|---|---|---|---|
| Kinesin-like protein KIF11 | Homo sapiens (human) | 0.0014 | |
| Nucleotide-binding oligomerization domain-containing protein 2 | Homo sapiens (human) | 5.0119 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Avancès, C; Culine, S; El Demery, M; Iborra, F; Lamy, PJ; Pinguet, F | 1 |
1 review(s) available for atropine and docetaxel anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for atropine and docetaxel anhydrous
| Article | Year |
|---|---|
Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Atropine; Biomarkers, Tumor; Chromogranin A; Cisplatin; Docetaxel; Humans; Male; Phosphopyruvate Hydratase; Prostatic Neoplasms; Taxoids | 2007 |
1 other study(ies) available for atropine and docetaxel anhydrous
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |